Latest Cetuximab Stories
Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer THOUSAND
Company also announces designation of Orphan Drug Status by FDA for VTX-2337 in Ovarian Cancer SEATTLE, April 17, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc.
Additional preclinical data highlights the pharmacologic properties of PEGPH20 SAN DIEGO, April 8, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
Company leveraging the scalability of its proprietary platform and next generation sequencing to introduce a full line of multiplexed urine-based oncogene mutation assays with superb sensitivity
UVA study’s surprising finding: Direct treatment of tumor prolongs survival. Charlottesville, VA (PRWEB) March 11, 2014 Contrary to the standard approach
Incentives for Pathway Compliance, Reduced Hospitalization are Changing Treatment, According to Findings from Decision Resources Group BURLINGTON, Mass., March 4, 2014 /PRNewswire/ -- Decision
Data Support Ongoing Randomized Phase 2 Study in Recurrent or Metastatic Head and Neck Cancer SEATTLE, Feb. 20, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc.
WHIPPANY, N.J., Feb.
Clinical and Regulatory Plans for Two Lead Products Announced SAN DIEGO, Feb.
- Large; stout; burly.